Xiaohua Funing decoction ameliorates non-alcoholic fatty liver disease by modulating the gut microbiota and bile acids
Frontiers in Microbiology,
Год журнала:
2025,
Номер
16
Опубликована: Фев. 10, 2025
Introduction
The
gut
microbiota
and
bile
acids
(BAs)
have
emerged
as
factors
involved
in
the
development
of
non-alcoholic
fatty
liver
disease
(NAFLD).
Xiaohua
Funing
decoction
(XFD)
is
a
traditional
Chinese
medicine
formula
used
for
treatment
NAFLD.
Previous
studies
indicated
that
XFD
protects
function,
but
underlying
mechanism
remains
unclear.
Methods
In
this
study,
Wistar
rat
model
NAFLD
(Mod)
was
established
via
high-fat
diet.
effects
obeticholic
acid
(OCA)
on
Mod
rats
were
subsequently
evaluated.
control
(Con)
group
fed
standard
There
eight
each
group,
lasted
12
weeks.
Furthermore,
metagenomic
sequencing
BA
metabolomic
analyses
performed.
Results
Compared
to
Con
presented
significant
differences
body
weights;
serum
total
cholesterol
(TC)
triglyceride
(TG)
levels;
TG,
TC,
salt
hydrolase
levels
(
p
<
0.05
or
0.01).
Importantly,
OCA
administration
normalized
these
indicators
Pathology
white
fat
steatosis
observed
significantly
alleviated
groups
abundances
Bacteroidales_bacterium
,
Prevotella_
sp.,
bacterium_0.1xD8-71
unclassified_g_Turicibacter
different
from
those
0.01),
whereas
abundance
greater
group.
A
17,
24,
24
differentially
abundant
BAs
detected
feces,
liver,
samples
groups,
respectively
serum,
16,
23,
14
BAs,
respectively,
including
glycochenodeoxycholic
acid,
deoxycholic
murideoxycholic
lithocholic
23-nordeoxycholic
3β-ursodeoxycholic
acid.
addition,
identified
potential
biomarker
Discussion
summary,
our
experiments
revealed
regulates
providing
beneficial
lipid
accumulation
Язык: Английский
Emerging Biomarkers in Metabolomics: Advancements in Precision Health and Disease Diagnosis
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(23), С. 13190 - 13190
Опубликована: Дек. 8, 2024
Metabolomics
has
come
to
the
fore
as
an
efficient
tool
in
search
for
biomarkers
that
are
critical
precision
health
approaches
and
improved
diagnostics.
This
review
will
outline
recent
advances
biomarker
discovery
based
on
metabolomics,
focusing
metabolomics
reported
cancer,
neurodegenerative
disorders,
cardiovascular
diseases,
metabolic
health.
In
provides
evidence
unique
oncometabolites
important
early
disease
detection
monitoring
of
treatment
responses.
Metabolite
profiling
conditions
such
mental
disorders
can
offer
diagnosis
mechanisms
into
especially
Alzheimer's
Parkinson's
diseases.
addition
these,
lipid
other
metabolites
relating
promising
patient
stratification
personalized
treatment.
The
gut
microbiome
environmental
exposure
also
feature
among
influential
factors
because
they
sculpt
individual
profiles,
impacting
overall
Further,
we
discuss
technological
current
clinical
applications,
challenges
faced
by
validation
toward
medicine.
Finally,
this
discusses
future
opportunities
regarding
integration
routine
healthcare
enable
preventive
approaches.
Язык: Английский